Ubiquitination

Ubiquitination designates the post-translational modification process in which ubiquitin, a small regulatory protein, is covalently attached to substrate proteins, typically on lysine residues, altering their stability, localisation, or functional activity. This process involves sequential action of E1 activating enzymes, E2 conjugating enzymes, and E3 ligases that confer substrate specificity. Ubiquitination can signal proteasomal degradation, regulate protein-protein interactions, or modulate cellular signalling pathways depending on ubiquitin chain type and linkage pattern.

The biopharmaceutical industry studies ubiquitination as a key regulatory mechanism implicated in cancer, neurodegeneration, inflammation, and immune regulation. Drug discovery programmes target ubiquitin ligases, deubiquitinating enzymes, and related pathway components to modulate disease-relevant protein turnover. PROTAC technologies leverage ubiquitination by recruiting E3 ligases to induce selective degradation of target proteins, expanding the druggable space beyond conventional inhibition. Research employs ubiquitination profiling and proteomics to identify pathway disruptions and therapeutic opportunities. As targeted protein degradation advances and protein homeostasis becomes increasingly central to therapeutic strategy, ubiquitination remains a critical concept guiding modern drug development and enabling novel therapeutic modalities.